Martin I Belkin DO

Neuroimmunology/Multiple Sclerosis

Neurology, MIND Assistant Professor, Internal Medicine, Oakland University Wm Beaumont SOM

28595 Orchard Lake RdSte 200Farmington Hills, MI 48334
Phone+1 248-553-0010
Fax+1 248-553-5957

Dr. Belkin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Belkin's full profile Already have an account?

Education & Training

Michigan State University College of Osteopathic MedicineClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MI State License 1997 - 2028
AOA Board of Neurology and Psychiatry Neurology

Clinical Trials

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
TERMINATED
PHASE3

Publications & Presentations

PubMed

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.
Jeffrey Kaplan, Dana Beenstock, Martin Belkin, Heidi Crayton, Christopher Eckstein
Journal of Medical Economics. 2026-12-01
2 citations
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Peter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, Robert T Naismith, Robert J Fox
Multiple Sclerosis. 2026-01-01
Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.
Angela Sanchez, Elisa Sheng, Sarah Eagleman, James L Eubanks, Patricia Izbicki
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2025-04-16